

Replacing Biologic Injections With Oral Pills

Written by The Life Science Feed Editorial Team · Published 28 May 2026 · Edited by Sarah Mitchell

EDITORIAL & AI STANDARDS

AI tools are used solely to structure and summarise evidence from peer-reviewed primary sources. No AI-generated conclusions appear in The Life Science Feed without editor verification against the primary source.

REFERENCES

1. Strober B, Thaçi D, Sofen H, et al. Deucravacitinib versus placebo and apremilast in moderate-to-severe plaque psoriasis (POETYK PSO-2). *J Am Acad Dermatol*. 2023;88(1):29–39. <https://doi.org/10.1016/j.jaad.2022.07.002>
2. Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib in plaque psoriasis — efficacy and safety from POETYK PSO-1. *J Am Acad Dermatol*. 2023;88(1):40–51. <https://doi.org/10.1016/j.jaad.2022.08.061>
3. Papp K, Gordon K, Thaçi D, et al. Phase 2 trial of selective tyrosine kinase 2 inhibition in plaque psoriasis. *N Engl J Med*. 2018;379(14):1313–1321. <https://doi.org/10.1056/NEJMoa1806382>
4. Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast over 52 weeks (ESTEEM 2). *Br J Dermatol*. 2015;173(6):1387–1399. <https://doi.org/10.1111/bjd.14164>
5. Nogueira M, Puig L, Torres T. JAK inhibitors for psoriasis: focus on selective TYK2 inhibitors. *Drugs*. 2020;80(4):341–352. <https://doi.org/10.1007/s40265-020-01261-8>
6. Banfield C, Scaramozza M, Zhang W, et al. The safety, tolerability, pharmacokinetics, and pharmacodynamics of a TYK2/JAK1 inhibitor (brepocitinib): a phase 2a study. *Clin Pharmacol Ther*. 2018;104(5):901–913. <https://doi.org/10.1002/cpt.1061>

LICENCE & RIGHTS

© 2026 The Life Science Feed. All rights reserved. This content is produced for medical education purposes. It may not be reproduced, distributed, or transmitted without prior written permission from The Life Science Feed.

MEDICAL DISCLAIMER

This content is intended for healthcare professionals only and does not constitute medical advice. Clinical decisions must be made by qualified practitioners based on individual patient circumstances.

FOLLOW THE LIFE SCIENCE FEED

Instagram @lifesciencefeed **LinkedIn** linkedin.com/company/thelifesciencefeed

thelifesciencefeed.com